NCT03064620

Brief Summary

Objective: PCV effects on S. pneumoniae and S. aureus carriage in a population based study. The major specific aims:

  1. 1.To compare different PCV vaccination policies, by cross-sectional repeated surveillance of closely related populations living in regions with different vaccination policies.
  2. 2.To compare the epidemiology, predictors and outcomes of antibiotic resistant S. aureus and S. pneumoniae in different regions of the PICR.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12,800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

March 29, 2016

Completed
11 months until next milestone

First Posted

Study publicly available on registry

February 27, 2017

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2020

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

February 27, 2017

Status Verified

February 1, 2017

Enrollment Period

6.3 years

First QC Date

March 29, 2016

Last Update Submit

February 22, 2017

Conditions

Keywords

PCV effectsS. pneumoniae carriageS. aureus carriageIndirect vaccination effectsPalestinian-Israeli Collaborative Research (PICR)

Outcome Measures

Primary Outcomes (1)

  • S. pneumoniae carriage

    S. pneumoniae carriage of children and parents by the different groups

    1 Day

Secondary Outcomes (5)

  • Carriage of Vaccine-type S. pneumoniae

    1 Day

  • Carriage of antibiotic resistant S. pneumonia

    1 Day

  • Carriage of piliated S. pneumonia

    1 Day

  • Carriage of MRSA

    1 Day

  • S. aureus carriage

    1 Day

Study Arms (3)

Israel PCV13

Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.

Biological: PCV

East Jerusalem PCV13

Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.

Biological: PCV

Palestine PCV7 PCV10

Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.

Biological: PCV

Interventions

PCVBIOLOGICAL

PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011

Also known as: PCV7, PCV10, PCV13
East Jerusalem PCV13Israel PCV13Palestine PCV7 PCV10

Eligibility Criteria

AgeUp to 5 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Child (age 0-5y) \& Parent who attend pediatric clinics (for any reason), in the participating clinics during the surveillance periods.

You may qualify if:

  • Any child younger than 5 years, visiting the participating clinics during the surveillance period

You may not qualify if:

  • Older than 5 years
  • Previously participated in the study.
  • Sibling has participated in the study.
  • Parent does not agree to sign informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sheba Medical Center

Ramat Gan, Israel, 5265601, Israel

RECRUITING

Related Publications (4)

  • Daana M, Rahav G, Hamdan A, Thalji A, Jaar F, Abdeen Z, Jaber H, Goral A, Huppert A, Raz M, Regev-Yochay G; PICR study group. Measuring the effects of pneumococcal conjugate vaccine (PCV7) on Streptococcus pneumoniae carriage and antibiotic resistance: the Palestinian-Israeli Collaborative Research (PICR). Vaccine. 2015 Feb 18;33(8):1021-6. doi: 10.1016/j.vaccine.2015.01.003. Epub 2015 Jan 12.

    PMID: 25593104BACKGROUND
  • Southern J, Roizin H, Daana M, Rubin C, Hasleton S, Cohen A, Goral A, Rahav G, Raz M, Regev-Yochay G; PICR group. Varied utilisation of health provision by Arab and Jewish residents in Israel. Int J Equity Health. 2015 Aug 7;14:63. doi: 10.1186/s12939-015-0193-8.

    PMID: 26245327BACKGROUND
  • Regev-Yochay G, Abullaish I, Malley R, Shainberg B, Varon M, Roytman Y, Ziv A, Goral A, Elhamdany A, Rahav G, Raz M; Palestinian-Israeli Collaborative Research Study Group. Streptococcus pneumoniae carriage in the Gaza strip. PLoS One. 2012;7(4):e35061. doi: 10.1371/journal.pone.0035061. Epub 2012 Apr 23.

    PMID: 22539955BACKGROUND
  • Biber A, Abuelaish I, Rahav G, Raz M, Cohen L, Valinsky L, Taran D, Goral A, Elhamdany A, Regev-Yochay G; PICR Study Group. A typical hospital-acquired methicillin-resistant Staphylococcus aureus clone is widespread in the community in the Gaza strip. PLoS One. 2012;7(8):e42864. doi: 10.1371/journal.pone.0042864. Epub 2012 Aug 16.

    PMID: 22916171BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

S. aureus and S. pneumoniae

MeSH Terms

Interventions

10-valent pneumococcal conjugate vaccine

Study Officials

  • Dror Harats, Prof.

    IRB Committee Sheba Medical Center Israel

    STUDY CHAIR

Central Study Contacts

Gili Regev-Yochay, MD

CONTACT

Ziad Abdeen, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Infect Dis Epi Section, Gertner

Study Record Dates

First Submitted

March 29, 2016

First Posted

February 27, 2017

Study Start

April 1, 2014

Primary Completion

August 1, 2020

Study Completion

January 1, 2022

Last Updated

February 27, 2017

Record last verified: 2017-02

Data Sharing

IPD Sharing
Will not share

Locations